GlassScriptPhysician profile
Michael Loy
NPI 1952722357
$1,104.98
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $166 · 2020: $647 · 2021: $244 · 2022: $16.18 · 2024: $31.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $31.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $31.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $216.72 | 2021 | |
| Glaxosmithkline, LLC. | $169.83 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $159.56 | 2019-2020 | |
| Novo Nordisk INC | $147.37 | 2019-2020 | |
| Pfizer INC. | $89.44 | 2020 | |
| Neurocrine Biosciences, INC. | $42.48 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $41.32 | 2020 | |
| Amarin Pharma, INC. | $30.84 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $30.39 | 2020 | |
| Astellas Pharma US INC | $29.38 | 2020 | |
| Trice Medical, INC. | $27.50 | 2021 | |
| Kyowa Kirin, INC. | $17.75 | 2024 | Nourianz |
| Allergan, INC. | $16.76 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.67 | 2020 | |
| Merck Sharp & Dohme LLC | $14.43 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $14.37 | 2019 | |
| Optinose US, INC. | $14.33 | 2020 | |
| Ucb, INC. | $14.12 | 2024 | Nayzilam |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Loy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.